ALLMedicine™ Hidradenitis Suppurativa Center

Mar 28th, 2023 - Hidradenitis suppurativa should be recognised as a weight-related comorbidity in NICE guidelines on managing obesity.|2023|Hussain K,Khalil N,Patel NP,|

Mar 25th, 2023 - Hypoxia-inducible factor-1α (HIF-1α) is the master transcription factor of glycolysis, Th17 cell differentiation and suppression of regulatory T cells. In the skin and serum of patients with psoriasis vulgaris, increased expression of HIF-1α has b...

Mar 24th, 2023 - Hidradenitis suppurativa (HS) is a debilitating systemic inflammatory disease with limited treatment options. Although management through dietary and lifestyle changes is a primary interest of the HS patient community, there is lack of consensus r...

Mar 23rd, 2023 - Hidradenitis suppurativa (HS) is a common chronical condition. It is often resistant to conservative treatment and requires a wide and aggressive surgical approach to avoid recurrence. A prospective study was compared comparing the outcomes of tho...

Mar 19th, 2023 - Health disparities are differences in health or disease incidence, prevalence, severity, or disease burden that are experienced by disadvantaged populations. Their root causes are attributed in large part to socially determined factors, including ...

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Mar 10th, 2023 - The goal of enrollment will be up to 10 subjects, which is based on feasibility and access to suitable patients during the enrollment period. Subjects will be consented prior to any study procedure being performed. Surgical planning, approach and ...

Mar 9th, 2023 - Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin disorder, characterized by painful inflamed nodules, abscesses and tunnels in the skin folds such as the axilla, inguinal region and gluteal area. The primary...

Mar 7th, 2023 - Single center, open-label, baseline-controlled study evaluating the use of a Sciton fractionated ablative laser in the treatment of Hidradenitis Suppurativa (HS) scarring. The device is FDA approved for the treatment of scarring in all skin types....

Mar 7th, 2023 - Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despit...

Mar 7th, 2023 - This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study. The purpose of this study is to find out how safe spes...

Feb 22nd, 2023 - Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that typically presents as inflamed nodules, abscesses, and sinus tracts in the apocrine gland–bearing regions. Chronic pain, fatigue, and social isolation put patients with HS a.

Feb 14th, 2023 - When administered subcutaneously every 2 weeks, secukinumab was effective at improving signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adults up to 52 weeks, results from two pivotal phase 3 clinical trials showed. The fi.

Jan 31st, 2023 - The gyrate or cerebriform pattern of inflammatory, often pus-filled, subcutaneous tracts of the scalp pointed to a diagnosis of dissecting cellulitis. This patient did not have the fluctuant tracts frequently seen in more active disease but did ha.

Jan 17th, 2023 - Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. With nearly 600 patients enrolled in two parallel phase III trials, 45% a...

Dec 12th, 2022 - Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil disease, is a chronic, recurrent, inflammatory occlusive disease affecting the terminal follicular epithelium in apocrine gland–bearing skin areas. 1 HS manifests as painful nodu.